CA-AFFINITY
16.6.2022 12:02:09 CEST | Business Wire | Press release
Affinity , the relationship intelligence platform for dealmakers, and Dealroom.co, a global provider of data and intelligence on startups and tech ecosystems, today announced a partnership to provide the most powerful combination of predictive intelligence and relationship intelligence for dealmakers. The partnership will provide Affinity clients with additional data intelligence for over 1.7 million startups and 2.1 million organizations globally. Joint clients of both Affinity and Dealroom.co will be able to access even more insights through additional data columns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005042/en/
“Our clients use Affinity to find, manage, and close the most important deals, and using organizational data insights helps them to target the right organizations is a critical part of their success,“ said Ray Zhou , CEO of Affinity. “Adding Dealroom.co’s predictive intelligence data to Affinity will ensure they can do that faster and with more confidence than ever before. ”
Affinity’s platform will integrate Dealroom.co’s wide range of critical data to enrich organizational records with additional firmographic data, predictive data insights, and leading market momentum indicators (such as social engagement). This will enable investors, M&A professionals, and other dealmakers to deliver the most complete understanding of deal opportunities and reduce the time they spend deciding which deals or organizations to focus on. Joint clients of both organizations will also receive access to additional Dealroom.co data columns in Affinity, including app downloads, website traffic, and founders’ history of success, further streamlining organizational intelligence gathering.
“As the intelligence layer for tech ecosystems, we help clients discover the world’s most promising companies through predictive intelligence,” said Yoram Wijngaarde , Founder and CEO at Dealroom.co. “This partnership puts this timely data into the hands of more investors around the world. We're excited to work with Affinity to provide investors with the data they need to be successful.”
Learn more about the power of Affinity and Dealroom.co’s data in the recently released joint report “Relationship Intelligence Benchmark Report: European Unicorn Edition ,” and watch the “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ” webinar which brings industry experts together to discuss the trends impacting dealmakers as well as the role relationship intelligence plays in the evolving market landscape.
Across the Affinity platform, over 500,000 new introductions are made and 450,000 deals are managed per month, helping dealmakers to find, manage, and close more deals. Currently, Affinity serves over 2,000 clients worldwide, including 500 in Europe where many already use Dealroom.co data in their dealmaking process. By capturing the exhaust of relationship interactions—over 18 trillion emails and 213 million calendar invites to date—Affinity automates the creation of contact and company records and tracks activity saving over 220 hours every year in data entry work.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations around the world. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
About Dealroom.co
Dealroom.co is the foremost data provider on startups, innovation, high-growth companies,
ecosystems, and emerging tech. Founded in Amsterdam in 2013, Dealroom.co works with many of the world’s most prominent investors, entrepreneurs, and government organizations to provide transparency, analysis, and insights on venture capital activity. Dealroom.co mission is to accelerate entrepreneurship and innovation through data, insights, and predictive intelligence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom